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ABSTRACT
Objective: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida
albicans species, terconazole cream has not been been studied in patients with these infections. We
sought to assess the clinical and mycological efficacy of terconazole cream in women with non-C.
albicans vaginitis.
Methods: The records of patients who had received a 7-day course of terconazole cream for
culture-proved non-C, albicans vaginitis were reviewed. Data with regard to patient demographics,
clinical and mycologic response to therapy within 1 month of treatment, and outcome with other
antifungal therapies were analyzed.
Results: Twenty-eight patients received terconazole cream for non-C, albicans infections. Three
patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were
nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received
terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C.
parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted
a resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P
0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected
in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %)
patients remained uncured.
Conclusions: Terconazole cream may be an appropriate first-line treatment for non C. albicans
vaginitis, even in patients who have previously received the drug. Infect. Dis. Obstet. Gynecol.
8:240-243, 2000. (C) 2ooo Wiley-Liss, Inc.
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ungal vaginitis is one of the most common
causes of vaginitis. It is estimated that 13 mil-
lion cases of vulvovaginal candidiasis (VVC) occur
in the United States annually. 1,e Although most of
these infections are caused by Candida albicans, re-
cent studies show that non-C, albicans species ac-
count for a significant proportion of cases referred
to subspeciality clinics. In 1986, O’Conner and
Sobel3 found that 21% of 115 women with recur-
rent VVC had non-C albicans species. Other cen-
ters have found 32% ofVVC resulting from to non-
C. albicans species in Philadelphia,4 19% in Pavia,
Italy,s and 50% in Rome.6 Although these studies
represent diverse populations, it is clear that non-C.
albicans are significant pathogens, regardless of ge-
ography, and concerns have been raised that infec-
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TABLE I. Clinical and mycologic cure with different vaginal isolates
C. glabrata (n 20) C. parapsilosis (n 3) C. lusitaniae (n 2) Total (n 25)
Clinical cure (%) 8 (40) 2 (66) (50) II (44)
Mycologic cure (%) 10 (50) 2 (66) 2 (I 00) 14 (56)
Negative smear (%) 12 (60) 2 (66) 2 (I 00) 16 (64)
tions with these pathogens are occurring more fre-
quently.
Terconazole is approved by the Food and Drug
Administration for the treatment of fungal vagini-
tis. 7 Advertisements for terconazole have stressed
its effectiveness in non-C, albicans infections,s It
has been shown to have good in vitro and in vivo
effectiveness for C. albicans.9,1 However, our re-
view of the literature failed to uncover any clinical
data with regard to the use of terconazole cream for
non-C, albicans vaginitis. We report here our expe-
rience with women treated with a 7-day course of
intravaginal teraconazole for non-C, albicans vagini-
tis.
MATERIALS AND METHODS
The patient population consisted of women re-
ferred by private gynecologists from 1996 through
1998 for evaluation of chronic vaginal symptoms.
Each patient underwent an evaluation that in-
cluded a standardized history, pelvic examination,
vaginal pH determination, smears for saline and
potassium hydroxide microscopy, and fungal cul-
tures of the vulva and vagina. Fungal cultures were
plated on modified Sabouraud dextrose agar plates,
which were incubated for 7 days at 37C. Positive
cultures were evaluated for germ tube formation
for identification of C. albicans species. Germ tube-
negative isolates were further speciated with the
Yeast-Tek System (Remel, Lenexa, KS).
In our clinic, patients who had blastospores on
microscopy and no hyphae were offered a 7-day
course of 0.4% intravaginal terconazole cream for
presumed non-C, albicans infections. As part of our
routine follow-up of such patients, they were asked
to return immediately and month after treatment
to determine their clinical and mycologic response
to therapy. For the present study, the records of
patients with culture-proved non-C, albicans vagi-
nitis were retrospectively reviewed. Patients were
evaluated with regard to patient demographics,
clinical resolution of symptoms (clinical cure), and
status of month follow-up fungal culture (myco-
logic cure). For those patients whose cultures were
persistently positive, available data with regard to
results with other therapies were analyzed. Statis-
tical analysis was performed with the Epilnfo sta-
tistical software package v. 6.0 (Centers for Disease
Control and Prevention, Atlanta, GA).
RESULTS
Twenty-eight patients were given terconazole
cream for non-C, albicans infections. Three patients
did not return for follow-up and were excluded
from further analysis. The median age was 45 years
(range 14-78). Seven women were nulliparous
(28%). Nine (36%) were menopausal; eight of them
were on some form of estrogen replacement
therapy. Seven patients (28%) had findings sugges-
tive of a nonneoplastic vulvar epithelial skin disor-
der. Among these patients, four had lichen sclero-
sus, two had squamous epithelial hyperplasia, and
one had lichen planus. Fourteen patients (56%)
had burning, thirteen (52%) had itching, and nine
(36%) complained of dyspareunia. The mean du-
ration of symptoms was 3 years (range 0.3-22).
Nine patients (36%) had used terconazole within
the last 6 months.
C. glabrata was isolated in 20 patients (80%), C.
parapsilosis in three patients (12%), and C. lusitaniae
in two patients (8%). Fourteen patients (56%)
achieved mycologic cure with terconazole cream;
among them, 11 patients (79%) noted resolution of
their symptoms in conjunction with the mycologi-
cal cure. Overall, 11 (44%) patients still had posi-
tive fungal cultures following terconazole therapy.
Table shows the rates of clinical and mycologic
cure by species. Prior terconazole use was not as-
sociated with failure of treatment (P 0.09). Four
of ten (40%) patients with positive follow-up cul-
tures were successfully treated with boric acid vagi-
nal suppositories. Three patients were given flucy-
tosine vaginal cream; two (67%) of them achieved
mycologic cure. Five patients (20%) remained un-
cured with any of these modalities.
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DISCUSSION
Because most vaginal yeast infections are caused
by C. albicans, clinical studies of terconazole have
essentially been studies of C. albicans infec-
tions. 11,1z In 1989, a multicenter trial evaluated the
clinical effectiveness of terconazole cream in the
treatment of C. albicans vaginitis. The clinical cure
rate was 87-95%; the mycologic cure rate was 77-
91%. lz In that study, C. albicans was the causative
organism of infection, and there were no patients
with non-C, albicans infections. As a triazole anti-
fungal agent, terconazole theoretically should have
a relatively broad spectrum of antifungal efficacy.
As a result, the drug has been extensively mar-
keted for non-C, albicans vaginitis7 and is widely
accepted as first-line treatment for this type of in-
fection. However, clinical data supporting this sup-
position are to our knowledge nonexistent.
In vitro, terconazole has been evaluated by
Lynch and Sobel. 13 Among 100 isolates of C. albi-
cans, 39 isolates of C. glabrata, 26 isolates of C.
parapsilosis, and seven isolates of C. tropicalis tested
for resistance to amphotericin B, 5-flourocytosine,
ketoconazole, clotrimazole, miconazole, tercona-
zole, itraconazole, saperconazole, and fluconazole,
the authors found that non-C, albicans species, es-
pecially C. glabrata, had severalfold increases in
MICs to all the azole antifungals but remained sen-
sitive to amphotericin and 5-fluorocytosine. C. al-
bicans and C. parapsilosis were highly sensitive to all
antifungals tested. Surprisingly, terconazole had up
to twofold higher MICs for Candida species than
the other topical azoles tested. This result suggests
that terconazole may actually be inferior to other
azole antifungal agents for these vaginal infections.
However, MICs do not seem to predict clinical sus-
ceptibility reliably and may vary extensively from
one laboratory to another.14-6 Furthermore, it is
unclear whether MICs, which are essentially mea-
sures meant to mimic drug-organism interactions
in blood stream infections, are applicable to the
vagina, where there are greater quantities of both
organism and medication. Therefore, given the
concerns raised by laboratory data and the possibly
increasing emergence of non-C, albicans infections,
a review of clinical outcomes in a selected group of
patients is important to guide clinical decision
making.
This retrospective study demonstrates that a
7-day course of terconazole cream resulted in a my-
cological cure in 56% of patients with non-C, albi-
cans yeast infections. However, our results are sub-
ject to certain limitations. Because our patient
population is derived from a tertiary care referral
center, most of these patients had been suffering
from vaginal symptoms for years and had previ-
ously tried many different therapies, including
multiple azole preparations. Although our data sug-
gest that prior terconazole use was not statistically
associated with current treatment failure, it is pos-
sible that terconazole cream would be even more
effective in a less refractory patient population.
Furthermore, in the 28% of patients with an asso-
ciated nonneoplastic vulvar epithelial skin disor-
der, the yeast may have been more difficult to treat
because of a deficiency in the local skin defenses.
Finally, the retrospective nature of our study fails
to account for the significant number of patients
who refused to use terconazole because they had
used it in the past without benefit and did not want
to waste their time with another course.
Non-C. albicans vaginitis patients present a
unique therapeutic challenge, particularly when
they fail conventional therapy. In a previous study
from our center, we found that, among 34 women
with non-C, albicans vaginitis, 20 were cured with
either fluconazole (2/8 patients), itraconazole (3/6),
clotrimazole (4/7), or boric acid suppositories (11/
13).4 Other studies, also limited to case series, sup-
port the use of flucytosine cream, boric acid, or
combination therapy in this difficult patient popu-
lation. In 1985, Horowitz et al. 17 compared 18 pa-
tients with C. tropicalis vaginitis to 81 patients with
C. albicans vaginitis. Patients with C. tropicalis had a
higher rate of recurrence (33%), and their infec-
tions tended to be resistant to miconazole cream,
1% clotrimazole cream, oral ketoconazole, and 1%
aqueous gentian violet lotion. None of the six pa-
tients with recurrent C. tropicalis vaginitis was
cured by any treatment. However, in a follow-up
study, 18 15 patients with C. tropicalis infections re-
sponded to flucytosine, although the length of fol-
low-up is not clear. Sobel and Chaim19 reviewed
the charts of 80 women with C. glabrata infections
who had been treated with boric acid suppositories.
They found that boric acid resulted in a mycologic
cure in 50% of patients. Finally, White and col-
leaguesz looked at three cases of C. glabrata vagi-
nitis that were clinically resistant to fluconazole,
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itraconazole, or nystatin pessaries; two responded
to prolonged treatment with itraconazole in conjuc-
tion with nystatin pessaries.
The paucity of clinical data with regard to non-
C. albicans vaginitis underscores the need for pro-
spective studies to address the best methods for
treatment. However, the feasibility of such studies
is severely limited, insofar as these infections are
often identified at referral centers, which may se-
lect for a more difficult patient population, and be-
cause there is currently no surveillance of these
infections in other women. Nevertheless, our re-
sults suggest that terconazole has at least some role
to play in management of these women and may be
comparable to other potential treatment modali-
ties.
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